SMA
-
Nusinersen Data Reinforces Biogen’s Dedication to SMA Outcome Improvement Through Clinical Research
Biogen released positive new data on its SMA treatment, SPINRAZA (nusinersen). Findings from the DEVOTE and NURTURE trials highlight the drug’s continued efficacy. The DEVOTE data suggests potential benefits from a higher dose regimen for previously treated patients, showing functional improvements across different patient groups. The final NURTURE study results reinforce the value of early intervention, demonstrating long-term benefits and safety. Biogen is awaiting regulatory approvals for the new higher dose regimen.
